

CERTIFICATE

Survey of 08 September 2023

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 33 - Emicizumab (506):


Validity 12 months:

Emicizumab

(R) analysis is subject to the RiLiBÄK

Customer:
10016818
Laboratorium
für Klinische Forschung GmbH
Lise-Meitner Str. 25-29
24223 Schwentental

Düsseldorf, 06 November 2023



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

